Extended in vivo blood circulation time of fluorinated liposomes  by Santaella, Catherine et al.
Volume 336, number 3, 481484 FEBS 13463 
0 1993 Federation of European Biochemical Societies 00145793/931$6.00 
December 1993 
Extended in vivo blood circulation time of fluorinated liposomes 
Catherine Santaella, FrCdCric FrCzard, Pierre Vierling*, Jean G. Riess* 
Laboratoire de Chimie Molkulaire, URA 426 au CNRS, Fact& des Sciences, UniversitC de Nice-Sophia Antipolis, 
06108 Nice Ckdex 02. France 
Received 12 October 1993; revised version received 15 November 1993 
The clearance from blood circulation of fluorinated liposomes made with pertluoroalkylated phosphatidylcholines was investigated in mice using 
liposome-entrapped 5(6)-carboxyfluoresceiein. The presence of a fluorinated core inside the membrane strongly retards their blood clearance. The 
fluorinated vesicles showed circulation half-lives of up to 8.6 h, which are 613 and 36 times larger than those of similarly sized conventional 
distearoylphosphatidylcholine and distearoylphosphatidylcholine/cholesterol lip somes, respectively. Their blood clearance was similar to that of 
some polyethylene glycol (PEG)-labelled ‘stealth’ liposomes and was dose-independent in a 3.3-330 WoYkg body weight dose range. 
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1. INTRODUCTION 
The use of liposomes as drug carrier and delivery 
systems is currently a topic of intensive investigation [ 11. 
In the last few years much effort has focussed on the 
development of vesicles which evade the mononuclear 
phagocytic system (MPS) and, consequently, exhibit 
prolonged circulation times in the blood stream. Signif- 
icant advances were achieved in this respect by includ- 
ing some specific natural glycolipids (such as the mon- 
osialylganglioside, G& in order to mimick the outer 
composition of the red blood cell membrane [2,3] and 
more recently by using synthetic phospholipids with 
hydrophilic, bulky and mobile polyethylene glycol 
(PEG) groups [4-6]. Such sterically stabilized PEG-li- 
posomes show prolonged circulating times in blood, 
irrespective of the dose administered, surface charge 
density, bilayer composition and fluidity [5,7,8]. How- 
ever, the modifications made in view of extending the 
intravascular persistence have as yet mainly been con- 
cerned with the composition and aspect of the surface 
of the liposomes. 
Liposome clearance from the blood stream occurs as 
a result of interactions with blood proteins and other 
plasma components, resulting in liposomes opsoniza- 
tion followed by macrophage uptake, and/or to li- 
posome disintegration by lipid exchange and depletion 
[ 1,9]. In order to reduce the MPS uptake and to enhance 
the circulation times of liposomes after i.v. administra- 
tion, we have examined the possibility of reducing these 
interactions by endowing the liposomal membrane with 
some of the characteristic properties of fluorine, i.e. its 
low affinity for lipidic phases. The highly stable fluori- 
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nated liposomes investigated here are made from syn- 
thetic phospholipids having perlluoroalkylated tails in 
their hydrophobic acyl chains (see Fig. 1) [lO,ll]. We 
have already shown that the presence of a fluorinated 
core inside the membrane enhances the retention of a 
water-soluble drug model, including human serum [ 121, 
and strongly decreases the membrane’s affinity for a 
lipophilic probe [ 131. 
In this paper we report the impact of the use of fluor- 
inated phosphatidylcholines on the intravascular persis- 
tence of liposomes in mice. We have also examined the 
effect of the fluorinated liposomes’ membrane composi- 
tion and size, and the dose dependence on their clear- 
ance from circulation. Our results show that fluorinated 
liposomes have circulating times in the blood stream 
higher than those of conventional distearoylphosphati- 
dylcholine (DSPC) or even distearoylphosphatidyl- 
choline/cholesterol (DSPCKH) liposomes of similar 
sizes. Their intravascular persistence was comparable to 
that of some PEG-derivatized liposomes. Most interest- 
ingly, we found also that the blood clearance of the 
fluorinated liposomes was dose-independent over a 
dose range of 3.3-330 pmol/kg mouse body weight. 
2. MATERIALS AND METHODS 
2.1. Materials 
The fluorinated F6CllPC and F8C5PC phospholipids (see Fig. 1) 
were synthesized according to Ill]. Their purity was assessed by ‘H 
and 3’P NMR, and TLC. 5(6)-CarboxytIuorescein (CF, HPLC Grade 
99%) was purchased from Sigma. Phosphate-buffered saline (PBS, 
injection grade) came from Biomerieux. All containers and fluids used 
in these experiments were sterile and pyrogen-free. 
2.2. Preparation of the liposomes 
The phospholipids (50-70 mM) were hydrated above their respec- 
tive phase transition (T, = 51°C for F6Cl lPC, 69°C for F8C5PC) in 
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Fig. 1. Structure of the fluorinated phospholipids, membranes and liposomes. 
a 100 mM CF solution (pH 7.4), followed by several cooling-heating 
cycles through the T,. The crude dispersion was then sonicated using 
a tip sonicator to produce small unilamellar vesicles of 5&70 nm. To 
avoid membrane defects arising from sonication, the vesicles were 
annealed for 1 h above their respective T, and then aged for 1248 h 
at room temperature until they reached the desired mean diameter. 
Free CF was then separated from the liposome-entrapped dye by gel 
filtration on a Sephadex G-50 column equilibrated in PBS. Liposome 
sizes, which are listed in Table I, were measured by dynamic light 
scattering using a Coulter model N4MD sub-micron particle analyzer. 
The samples gave good fits with a unimodal population (polydisper- 
sity 0.14.18 for F6CllPC, 0.29 for F8CSPC). 
Phospholipid concentration was determined by a phosphate assay 
[14] or by “F NMR, using CF,CH,OH as an internal standard. Lipo- 
somal CF was measured in appropriately diluted samples before and 
after addition of 10% sodium deoxycholate (DOC) on a Perkin Elmer 
LSSOB spectrofluorimeter, using excitation and emission wavelengths 
of 480 mn and 520 nm, respectively. Latent CF, which is the fraction 
of encapsulated CF, was calculated as 100 x (& - FJF, where FT and 
F, denote the total fluorescence (after the liposomes had been de- 
stroyed by DOC) and free (released) dye, respectively. 
2.3. In vivo experiments 
OF1 Dawley male mice (3-5 per group, two independent experi- 
ments on 3 animals, n = 6, or a single one on 5 animals, n = 5) in the 
weight range 25-33 g were injected into the tail vein with the liposomal 
preparations at a dose of 0.1-10 pmol of phospholipid per mouse (ca 
3.>330 pmol/kg mice body weight). At selected times post injection, 
30 ~1 of blood was collected from the tail vein in heparinized micro- 
pipettes and rapidly mixed with 2.5 ml of PBS. The samples were spun 
out at 3,000 rpm for 10 min. The supematant was analyzed for CF 
before and after addition of DOC. Latent CF was determined and 
expressed as % of CF latency in the respective liposomal preparation 
before the injection. The data were analyzed using the appropriate 
Student’s t-test and found statistically significant (P 5 0.05). 
2.4. In vitro experiments 
CF-loaded liposomes prepared from F6CIlPC or F8C5PC were 
incubated at 37’C in a fresh mouse blood/heparine mixture or in 
human serum. The volume ratio of bloodniposomes was similar to 
that expected after iv. injection (assuming blood volume to be 1115 
of body weight in mice) for doses in the 3.3-33Opmol/kg animal body 
weight range. When incubated with blood, the samples were shaken 
at 120 strokes/min. At selected times, 30~1 samples were collected and 
assayed for CF latency as for the in vivo experiments. For the exper- 
iments run in human serum, 30-50 ,~l of the liposomal preparations 
were mixed with 2 ml of serum. At selected times 20 ~1 were collected, 
diluted in 0.15 M NaCl, 20 mM HEPES buffer and assayed for CF 
latency. Each experiment was performed at least in triplicate. 
Table I 
Effect of lipid composition and liposome size on circulating half-times (t,,J and % of injected dose present in circulation after various times 
post-injection, for fluorinated, conventional or polyethyleneglycol (PEG)-derivatized liposomes after intravenous injection in mice 
Lipid composition Size f SD. 
(nm) 
Injected dose 
Olmofig 
body weight) 
Circulating 
half-time 
(h) 
% injected 
dose 
Reference 
F6CllPC 
F6CllPC 
F8C5PC 
DSPC 
DSPC 
DSPC/CH l/l 
DSPC/CH l/l 
DSPC/PEGllO 9/l 
DSPCIPEG5000 9/l 
DSPUPEGl900 l/O.1 
DSPCUUPEG2000 l/l/O.6 
110f 30 
170f 50 
210f 80 
30-60 
150 
50 
200 
90 
90 
112-136 
18&200 
40 
40 
40 
45 
55 
33 
33 
55 
55 
20 
30 
8.6 
6 
4.2 
1.5 
0.47 
7.5 
1.5 
9.52 
8.4 
_ 
_ 
77” 
66” 
58” 
-10” 
-80” 
-20” 
-85 
-80 
-44s 
-50’ 
d 
d 
A 
161 
WI 
P81 
]7,l91 
[201 
[201 
]2ll 
“2 h post-injection, extrapolated from the curves. ‘After 24 h. ‘3h post-injection. dThis work 
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Fig. 2. Blood clearance of fluorinated liposomes after i.v. injection in 
mice at a dose of 40 ,fnnollkg body weight. Data are expressed as 
mean rt S.D. (n = 5 or 6). When no errors bars are seen, standard 
deviation is smaller than the data points. (0) 110 nm-sized F6CllPC 
vesicles; (e) 170 rmr-sized F6CllPC vesicles; (r) 210 nm-sized 
F8CSPC vesicles. 
3. RESULTS 
To examine the clearance of the ~uo~nated liposome 
from blood circulation, we have used S(6)-carboxyfluo- 
rescein (CF) as a marker of their internal aqueous 
space. This technique has proved a convenient and ac- 
curate means of dete~ning the half-life of the vesicles 
in circulation [I 51. In order to measure vesicle clearance 
we have first assessed the extent of leakage of the fluor- 
inated liposomes in vitro when incubated in human 
serum and in mouse blood in conditions close to those 
encountered in vivo. It was found that the fluorinated 
liposomes display in human serum and in mouse blood 
a high stability with respect o CF leakage. The kinetics 
of CF release were indeed very slow: less than 56% of 
CF release over a period of 24 h. It also appears that 
passive adsorption of the fluorinated vesicles onto 
erythrocytes does not contribute significantly to their in 
vivo clearance. CF late&es for fluo~nat~ liposomes 
incubated at 37°C in mouse blood were indeed found 
comparable to those determined for vesicles conse- 
quently diluted in a 0.15 M NaCl, 20 mM HEPES 
buffer. 
Fig. 2 shows the clearance of the fluorinated vesicles 
from the blood stream as a function of time after an i.v. 
administration in mice of differently sized vesicles made 
from F6CllPC (110 and 170 nm) or F8C5PC (210 mn) 
at a dose of 1.2 pmol/30 g mouse. The kinetics fitted 
monoexponential decays. The circulating half-lives, f1,2, 
calculated from these curves are presented in Table I 
together with data selected from the literature showing 
the effects of liposome composition and size on t,,2 and 
% of injected doses present 2 h after injection for con- 
ventional and PEG derivatized liposomes after iv. in- 
jection in mice. 
Fig. 3 illustrates the blood level of the 110 m-sized 
F6CllPC SUVs measured at 15 min and 2 h after iv. 
a~nistration for injected doses ranging from 3.3 to 
330 ,urnol/kg mouse body weight. It indicates that the 
clearance from the blood stream of these fluorinated 
liposomes is apparently do~“independent in the dose 
range investigated. 
4. DISCUSSION 
The main objectives of this study were to evaluate the 
impact on blood clearance of the presence of a fluori- 
nated core within the membrane of liposomes made 
from fluorinated phosphatidylcholines (Fig. 1). We 
have also examined the effects of the fluorinated vesi- 
cles’ size and dose on their clearance. These parameters 
are known, among others, to influence the intravascular 
persistence and biodist~bution of conventional lipo- 
somes made from synthetic or natural phosphati- 
dylcholines [161. The impact of the fluorinated compart- 
ment was retrieved from a comparison of the fluori- 
nated vesicles’ clearance to that of liposomes made from 
the structurally closely related hydrogenated analog, 
DSPC (among the hydrogenated phosphatidylcholines, 
DSPC-based liposomes possess one of the highest intra- 
vascular persistences). 
The most important finding of this study is that the 
presence of a fluorinated core inside the liposomal 
membrane strongly increases the blood circulation 
times of the vesicles, including large-sized ones: the t,,2 
measured for the F6CllPC and F8C5PC liposomes 
(Table I) are almost 6-13 times larger than those re- 
ported for similarly sized conventions DSPC li- 
posomes. Liposome stability and persistence in blood 
circulation may be improved by the inclusion in the 
membrane of the latter of high levels of cholesterol 
[16,17]. We found that the presence of a fluo~nated core 
within the membrane slowed down the liposomes’ blood 
clearance even more effectively than a high content of 
cholesterol. When compared to DSPC/CH l/l vesicles 
of similar size, the vesicles made from fluorinated 
phospholipids alone exhibited 3-6 times longer blood 
circulation times. Most interestingly, we found that the 
1 10 100 IO00 
Injected dose @mole/kg mouse body weight) 
Fig. 3. Blood clearance in mice of 110 nm-sized F6CllPC vesicles as 
a function of injected dose. Each point represents an average f: SD. 
(rz = 3-5). The results are plotted as the % of the injected dose present 
in blood: (0) I5 min post-injection; (0) 2 h post-injection. 
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F6Cl IPC liposomes display a blood clearance similar 
to that of some of the long-circulating PEG-labelled 
liposomes, the so-called ‘stealth’ liposomes (Table I). 
It is also noteworthy that the liposomes made of 
F6C1 IPC exhibit an almost dose-independent clearance 
over the 3.3-330 pmol/kg body weight range (Fig. 3), 
while saturation is generally observed for doses between 
X&100 PmoYkg in the case of conventional iposomes 
[181. 
The behaviour, in terms of high circulation half-times 
and dose-independence, of the fluorinated liposomes is 
comparable with that of PEG-derivatized vesicles which 
also show extended blood circulation times irrespective 
of dose for sizes below 200 nm. In the latter case, steric 
stabilization and surface mobility of the long polymeric 
PEG chains are thought to decrease opsonization and, 
consequently, the recognition and uptake of such li- 
posomes by the MPS [8]. In the case of the fluorinated 
liposomes, it is most likely the fluorinated core inside 
their membrane, with its lipophobic character, which is 
able to reduce the adsorption and anchoring of lipo- 
philic plasma proteins either onto the surface and/or 
more deeply into their membrane, thus inhibiting their 
recognition and uptake by the MPS. The high in vitro 
stability observed for the fluorinated liposomes both in 
serum [12] and in whole blood, as a result of an en- 
hanced hydrophobic character of the fluorinated mem- 
brane, may also account for a decrease in their disinte- 
gration and depletion through lipid exchange induced 
by plasma proteins and consequently for their extended 
blood circulation. 
Our results show further that not only direct modifi- 
cations of the liposomes’ surface are of prime impor- 
tance for evading in vivo recognition and MPS uptake, 
but also more subtle and a priori ‘invisible’ changes 
introduced inside the membrane, such as here with the 
presence of a fluorinated core within the membrane. 
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